Please login to the form below

Not currently logged in
Email:
Password:

stem cell therapy

This page shows the latest stem cell therapy news and features for those working in and with pharma, biotech and healthcare.

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

CTX001 is an investigational, autologous, gene-edited haematopoietic stem cell therapy for patients suffering from severe haemoglobinopathies. ... CTX001 is an investigational ex vivo CRISPR gene-edited therapy for patients suffering from β-thalassemia

Latest news

More from news
Approximately 3 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel),

  • Pharma deals continue to slide Pharma deals continue to slide

    This referred to the CAR-T therapy, Kymriah, from Novartis for treating a form of acute lymphoblastic leukaemia in children and young adults. ... 425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    Mock assessment of a CAR-T therapy. The hypothetical CAR-T therapy was tested in two different profiles: as a bridge to haematopoietic stem cell transplantation or as a curative therapy. ... If so, how much of the per-patient price could the cell therapy

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Stem cell therapy for HF is currently being led by the likes of Bioheart (recently renamed US Stem Cell), which has muscle stem cell therapy candidate Myocell in a phase III ... trial; Mesoblast/Teva with allogenic mesenchymal stem cell therapy Neofuse;

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    225. Athersys / Chugai. Licence and collaboration Japan. Phase 2 stem cell therapy for treatment of ischaemic stroke.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Dr Jay Stout moves from Merck to SanBio Dr Jay Stout moves from Merck to SanBio

    In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development. ... He is perhaps the individual with the greatest experience in the world in manufacturing

  • Plasticell names Aaron Chuang as chief scientific officer Plasticell names Aaron Chuang as chief scientific officer

    Chuang was an industrial advisor on high profile stem cell initiatives including UK Stem Cell Initiative, UK Cell Therapy Catapult and the California Institute of Regenerative Medicine. ... He was also prominent in establishing GSK's alliance with the

  • ReNeuron makes shifts and additions to senior team ReNeuron makes shifts and additions to senior team

    UK-based stem cell therapy company ReNeuron has announced a number of board and senior management changes. ... Dr Randolph Corteling has been promoted to head of research from his current role of head of cell biology after joining in 2007.

  • ReNeuron appoints new CEO ReNeuron appoints new CEO

    ReNeuron appoints new CEO. Olav Hellebø joins from Clavis Pharma. UK-based stem cell therapy company ReNeuron Group has appointed Olav Hellebø as its new CEO with immediate effect. ... ReNeuron's stem cell therapy candidates, will be the best way to

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • The gene therapy revolution

    And every new therapy will have its own specific challenges depending on the disease it is targeting. ... As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene

  • How do you define a biotech company?

    ReNeuron, a leading, clinical-stage stem cell business.

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    stem cell therapy and to learn his perspective on navigating the challenges that come with developing products in this complex market. ... The biotech creates ‘ off-the-shelf’ cell-based therapies, including a CTX stem cell therapy that aims to treat

  • Healthcare in the Digital Age

    Exciting developments in immunotherapy and oncology, and huge strides in gene and stem-cell therapy are matched by powerhouse collaborations between academia and industry that point to a golden age for

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics